Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

387
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
387
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

318
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
318
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

426
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
426
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

614
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
614
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

194
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
194
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

420
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
420

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Cognitive, Functional, and Behavioral Changes After Ventriculoperitoneal Shunt Surgery in Idiopathic Normal Pressure Hydrocephalus: A Multicenter Prospective Study.

World neurosurgery·2026
Same author

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.

The Journal of antimicrobial chemotherapy·2026
Same author

Evaluation of metformin for epilepsy prevention or seizure control in people without evidence of diabetes: retrospective cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Seizure prophylaxis in glioma surgery (SPRING): A multi-center, unblinded, randomized trial.

Neuro-oncology practice·2026
Same author

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
Same author

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.

Clinical pharmacology and therapeutics·2026

Related Experiment Video

Updated: Jul 13, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.1K

Immunomodulatory interventions for focal epilepsy.

Mariangela Panebianco1, Lauren Walker1, Anthony G Marson1

  • 1Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.

The Cochrane Database of Systematic Reviews
|October 16, 2023
PubMed
Summary

Immunomodulatory interventions effectively reduce seizure frequency in focal epilepsy patients when used alongside standard treatments. However, more research is needed to determine their tolerability and long-term effects in epilepsy management.

More Related Videos

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

2.5K
Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
09:06

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

9.6K

Related Experiment Videos

Last Updated: Jul 13, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.1K
Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala
09:49

Using a Bipolar Electrode to Create a Temporal Lobe Epilepsy Mouse Model by Electrical Kindling of the Amygdala

Published on: June 29, 2022

2.5K
Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
09:06

Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture

Published on: December 22, 2016

9.6K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Epilepsy affects 0.5-1% of the population, with up to 30% unresponsive to current pharmacological treatments.
  • Inflammatory pathways are implicated in epilepsy pathogenesis, suggesting immunomodulatory interventions as a novel therapeutic strategy.
  • This review updates a 2013 Cochrane Review on immunomodulatory interventions for focal epilepsy.

Approach:

  • Systematic review and meta-analysis of randomized placebo-controlled trials (RCTs) of add-on immunomodulatory therapies for focal epilepsy.
  • Searched major databases (Cochrane, Medline) up to November 2021, with no language restrictions.
  • Included RCTs with adequate randomization concealment, focusing on children (over 2 years) and adults with focal epilepsy.

Key Points:

  • Three RCTs involving 172 participants were included, with moderate-certainty evidence showing immunomodulatory interventions significantly reduce seizure frequency (RR 2.30, 95% CI 1.15-4.60).
  • Low-certainty evidence indicated no significant difference in treatment withdrawal (RR 1.04) or adverse effects (RR 1.16) compared to placebo.
  • Data on cognitive effects and quality of life were limited; some adverse effects like dizziness and fatigue were more frequent with immunomodulatory agents.

Conclusions:

  • Immunomodulatory interventions show efficacy in reducing seizure frequency for focal epilepsy in children and adults.
  • The tolerability of these interventions in epilepsy patients remains unclear due to limited data.
  • Further high-quality randomized controlled trials are necessary to establish the safety and efficacy profile.